Evidence map›Paper›PMID 29383151›Full record

ArticleOncotarget2017

High protein and mRNA expression levels of TUBB3 (class III ß-tubulin) are associated with aggressive tumor features in esophageal adenocarcinomas.

Heike Loeser, Simon Schallenberg, Moritz von Winterfeld, Lars Tharun, Hakan Alakus, Arnulf Hölscher, Elfriede Bollschweiler, Reinhard Buettner, Thomas Zander, Alexander Quaas

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Class IIIAnalytical cellular pathology (Amsterdam) · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Heike Loeser *Institute of Pathology, University of Cologne, Cologne, Germany.
Simon Schallenberg *Institute of Pathology, University of Cologne, Cologne, Germany.
Moritz von WinterfeldInstitute of Pathology, University of Cologne, Cologne, Germany.
Lars TharunInstitute of Pathology, University of Cologne, Cologne, Germany.
Hakan AlakusDepartment of General, Visceral and Cancer Surgery, University of Cologne, Cologne, Germany.
Arnulf HölscherDepartment of Thorax and Oesophageal Surgery, Agaplesion Markus Krankenhaus, Frankfurt/Main, Germany.
Elfriede BollschweilerDepartment of General, Visceral and Cancer Surgery, University of Cologne, Cologne, Germany.
Reinhard BuettnerInstitute of Pathology, University of Cologne, Cologne, Germany.
Thomas Zander *Department I of Internal Medicine, Center for Integrated Oncology (CIO), University of Cologne, Cologne, Germany.
Alexander Quaas *Institute of Pathology, University of Cologne, Cologne, Germany.
University of Cologne · DEAgaplesion Markus Hospital · DEUniversity Hospital Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEsophageal adenocarcinomas show an increasing incidence in the Western world and their overall survival remains low. Microtubules are multifunctional cytoskeletal proteins involved in crucial cellular roles, including maintenance of cell shape, intracellular transport, meiosis, and mitosis. Microtubulus-TUBB3 was found overexpressed in several carcinomas suggesting a significant role in cancer development. High levels of TUBB3 expression were also described to be associated with poor clinical outcome in various cancers. It was shown that overexpression of TUBB3 could be related to reduced efficiency of taxane-based targeting anticancer drugs in several cancer types.

resultsThere is a statistically significant association between high TUBB3 protein and TUBB3 mRNA expression and shortened survival (p<0,0001). Prognostic impact of TUBB3 expression is seen in patients with and without multimodal treatment. Multivariate analysis revealed a strong TUBB3 expression to be an independent prognosis factor. Validation of protein expression by mRNA in situ hybridization underlines the credibility of the immunohistochemical results. DISCUSSION: Our study emphasized the significant importance of TUBB3 in esophageal adenocarcinoma. TUBB3 serves as an independent prognostic marker and may be a valuable biomarker for routine application in esophageal adenocarcinoma especially to address the need for adjuvant treatment in individuals following neoadjuvant therapy and surgery. Future prospective studies are needed which include the results of TUBB3 in preoperative biopsy material to proof the prognostic impact of TUBB3. MATERIALS AND

methods280 esophageal adenocarcinomas that underwent primary surgical resection or resection after neoadjuvant therapy were analyzed by mRNA-in-situ-hybridization (RNAscope

Indexed as

esophageal adenocarcinomaimmunohistochemistryRNA-in-situ-hybridizationTUBB3

Identifiers

PMID29383151
PMCPMC5777763
OpenAlexW2772261825

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.